Sandoz Inc. v. Amgen Inc. Case Brief
Complete case briefs with LSD+
Every LSD.Law brief pairs a full IRAC analysis with opinion summaries at three levels of depth, written by a team of Harvard Law and MIT graduates - a quick synopsis when you are pressed for time, the complete reasoning when you need to go deep.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: The Supreme Court held that under the Biologics Price Competition and Innovation Act (BPCIA), a biosimilar drug applicant cannot be forced by federal injunction to share its application with the original drug maker, and may give its 180-day marketing notice before receiving FDA approval.
Legal Significance: This landmark decision clarified two key procedures in the BPCIA’s “patent dance,” granting biosimilar manufacturers significant strategic advantages by allowing them to control the timing of patent litigation and accelerate their products’ entry into the market.
Sandoz Inc. v. Amgen Inc. Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
The Biologics Price Competition and Innovation Act of 2009 (BPCIA) establishes a framework for resolving patent disputes between a biosimilar applicant and the sponsor of the original reference biologic. This framework, often called the “patent dance,” includes two key steps at issue. First, under 42 U.S.C. § 262(l)(2)(A), the biosimilar applicant “shall provide” its application and manufacturing information to the sponsor. Second, under § 262(l)(8)(A), the applicant “shall provide notice” to the sponsor at least 180 days before commercially marketing the biosimilar. Amgen Inc. manufactures the biologic Neupogen. Sandoz Inc. filed an application with the FDA for a biosimilar version, Zarxio. After the FDA accepted its application, Sandoz notified Amgen but expressly refused to provide its application and manufacturing information as specified in § 262(l)(2)(A). Sandoz also provided its 180-day notice of commercial marketing before the FDA had licensed Zarxio. Amgen sued, seeking a federal injunction to compel Sandoz to comply with the disclosure requirement and arguing that the pre-licensure marketing notice was invalid. Amgen also brought claims under California’s unfair competition law.
Court Holding & Legal Precedent
Issue: Under the Biologics Price Competition and Innovation Act, is a biosimilar applicant’s duty to disclose its application and manufacturing information enforceable by federal injunction, and must the applicant wait for FDA licensure before giving the 180-day notice of commercial marketing?
No. The Court held that a federal injunction is not available to Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo co
IRAC Legal Analysis
About IRAC analysis
IRAC (Issue, Rule, Analysis, Conclusion) is the structure professors expect in exam answers. Each LSD.Law brief states the issue, the governing rule with citations, the court's application of that rule, and the conclusion - the same reasoning pattern you will use on exams and in practice.
Legal Issue
Under the Biologics Price Competition and Innovation Act, is a biosimilar applicant’s duty to disclose its application and manufacturing information enforceable by federal injunction, and must the applicant wait for FDA licensure before giving the 180-day notice of commercial marketing?
Conclusion
This decision provides foundational guidance on the BPCIA's patent litigation framework, confirming Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
Legal Rule
First, the BPCIA's requirement that a biosimilar applicant provide its application and Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit ani
Legal Analysis
The Court's decision rested on a close textual analysis of the BPCIA's Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id es
Flash-to-Full Case Opinions
Flash Summary
- A biosimilar applicant cannot be forced by a federal injunction to